Acet-Öztürk, Nilüfer AylinÖmer-Topcu, DilaraVurat Acar, KübraAydın-Güçlü, ÖzgePınar, İbrahim EthemDemirdoğen, EzgiGörek-Dilektasli, AslıKazak, EsraÖzkocaman, VildanUrsavaş, AhmetÖzkalemkaş, FahirEner, BeyzaAli, RıdvanAkalın, Halis2024-09-092024-09-092023-10-160934-9723https://doi.org/10.1007/s10096-023-04686-7https://link.springer.com/article/10.1007/s10096-023-04686-7https://hdl.handle.net/11452/44394BackgroundDiagnostic accuracy of galactomannan measurements is highly variable depending on the study population, diagnostic procedures, and treatment procedures. We aimed to evaluate the effect of posaconazole prophylaxis and empiric antifungal treatment upon diagnostic accuracy of GM measurements in bronchoalveolar lavage (BAL), bronchial lavage (BL), and serum in hematological malignancy population.MethodsPatients hospitalized in a single tertiary care center with hematologic malignancies undergoing fiberoptic bronchoscopy (FOB) with a preliminary diagnosis of IPA were retrospectively included.ResultsIn all the study population (n = 327), AUC for BAL, BL, and serum GM were as follows: 0.731 [0.666-0.790], 0.869 [0.816-0.912], and 0.610 [0.540-0.676] with BL samples having the best diagnostic value. GM measurements in patients under posaconazole prophylaxis (n = 114) showed similar diagnostic performance. While specificity was similar between patients with and without posaconazole prophylaxis, sensitivity of GM measurements was lower in patients with prophylaxis. Analyses with patient classified according to antifungal treatment at the time of FOB procedure (n = 166) showed a decreased diagnostic accuracy in serum GM and BAL GM measurements related with the duration of treatment. However, BAL, BL, and serum GM measurements presented similar sensitivity and specificity in higher cut-off values in longer durations of antifungal treatment.ConclusionOur study shows that posaconazole prophylaxis and active short-term (3 days) antifungal treatment do not significantly affect overall diagnostic performance of GM measurements in bronchoalveolar lavage and bronchial lavage samples. However, using different cut-off values for patients receiving active treatment might be suggested to increase sensitivity.eninfo:eu-repo/semantics/closedAccessBronchoalveolar lavage fluidInvasive pulmonary aspergillosisInfectious-diseases societyGalactomannan enzyme-immunoassayPractice guidelinesDiagnosisManagementAssaySensitivityKineticsGalactomannan diagnostic performanceBronchoalveolar lavageAntifungal therapyInfectious diseasesMicrobiologyArticle001096591600001334343110.1007/s10096-023-04686-7